GlycoTech Corporation Information

GlycoTech has maintained a corporate alliance with Novartis for the past six years to develop small molecule mimics of carbohydrate ligands as potent antagonists for the aberrant extravasation of lymphocytes from the bloodstream during transplantation-induced reperfusion injury. In addition, licensing agreements were recently established with Chiron Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor markers owned by GlycoTech. Research agreements have also been established with the National Institutes of Health, the University of Pennsylvania, the University of Rochester, and the Chicago Institute for Neurosurgery and Neuroresearch. GlycoTech is actively seeking other pharmaceutical partners and offers a combined range of expertise focusing on the Glycobiology area. The corporate structure and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and avoid the obligations encountered with the fixed financial responsibilities associated with internal organic growth. We welcome the opportunity to meet with all interested parties to explore mutually constructive collaborations.